|
|
|
|
|
Last Trade
|
Last Trade:
$299.00
|
Change:
4.71 (1.60%)
|
Trade Time:
01:17 PM EST
|
Market Cap:
$76.68B
|
|
|
|
|
|
|
Description of Business
|
|
We are a global biotechnology company that invests in scientific innovation to
create transformative medicines for people with serious diseases with a focus on
specialty markets. We have multiple approved medicines that treat the underlying
cause of cystic fibrosis, or CF, a life-threatening genetic disease, and we have
several ongoing clinical and research programs to advance and extend treatment
of CF. Beyond CF, we have a pipeline of investigational therapies in other
serious diseases where we are leveraging insight into causal human biology,
including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease,
type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies.
Marketed Products
Our goal in CF is to develop treatment regimens that will provide benefits to
all people with CF and will enhance the benefits currently provided to people
taking our medicines.
|
|
|
|